Targeting type-2 inflammation in pulmonary hypertension: lessons from a novel model

Navneet Singh¹, William M Oldham^{2

3}

Affiliations

¹ Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, The Warren Alpert School of Medicine, Brown University, Providence, Rhode Island, United States.
² Division of Pulmonary and Critical Care Medicine, Department of Medicine, Harvard Medical School, Boston, Massachusetts, United States.
³ Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States.

Comment

Navneet Singh et al. Am J Physiol Lung Cell Mol Physiol. 2025.

. 2025 May 1;328(5):L669-L670.

doi: 10.1152/ajplung.00109.2025. Epub 2025 Apr 7.

Navneet Singh¹, William M Oldham^{2

3}

¹ Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, The Warren Alpert School of Medicine, Brown University, Providence, Rhode Island, United States.
² Division of Pulmonary and Critical Care Medicine, Department of Medicine, Harvard Medical School, Boston, Massachusetts, United States.
³ Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States.

No abstract available

Keywords: Fra-2; pulmonary fibrosis; pulmonary hypertension; type 2 inflammation.

Comment on

Pulmonary vascular remodeling in Fra-2 transgenic mice is driven by type 2 inflammation and accompanied by pulmonary vascular hyperresponsiveness.
Birnhuber A, Biasin V, Jain PP, Kwiatkowski G, Boiarina E, Wilhelm J, Ahrens K, Nagaraj C, Olschewski A, Witzenrath M, Chlopicki S, Marsh LM, Tabeling C, Kwapiszewska G. Birnhuber A, et al. Am J Physiol Lung Cell Mol Physiol. 2025 Mar 1;328(3):L413-L429. doi: 10.1152/ajplung.00274.2024. Epub 2025 Feb 4. Am J Physiol Lung Cell Mol Physiol. 2025. PMID: 39903186 Free PMC article.

1. Rabinovitch M, Guignabert C, Humbert M, Nicolls MR. Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension. Circulation research 2014;115(1):165–175. - PMC - PubMed
1. Chaisson NF, Hassoun PM. Systemic sclerosis-associated pulmonary arterial hypertension. Chest 2013;144(4):1346–1356. - PMC - PubMed
1. Weatherald J, Montani D, Jevnikar M, Jaïs X, Savale L, Humbert M. Screening for pulmonary arterial hypertension in systemic sclerosis. European Respiratory Review 2019;28(153):190023. DOI: 10.1183/16000617.0023-2019. - DOI - PMC - PubMed
1. Zamanian RT, Badesch D, Chung L, et al. Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of Systemic Sclerosis-associated Pulmonary Arterial Hypertension: A Multicenter, Double-Blind, Randomized, Placebo-controlled Trial. Am J Respir Crit Care Med 2021;204(2):209–221. (In eng). DOI: 10.1164/rccm.202009-3481OC. - DOI - PMC - PubMed
1. Birnhuber A, Biasin V, Jain PP, et al. Pulmonary vascular remodeling in Fra-2 transgenic mice is driven by type 2 inflammation and accompanied by pulmonary vascular hyperresponsiveness. Am J Physiol Lung Cell Mol Physiol 2025;328(3):L413–L429. DOI: 10.1152/ajplung.00274.2024. - DOI - PMC - PubMed